All filters
Abstracts
Factors associated with the emergence of resistance mutations in patients failing dual or triple-integrase inhibitors-based regimen in a French national survey
A. Marcelin Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
HIV DNA drug resistance genotyping, based on illumina sequencing, as decisional marker for cart opimisation in clinical practice: added value, gaps and future directions
A. Si-Mohammed Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
High efficacy after switching to integrase strand transfer inhibitors (INSTI) in PLWH with undetectable viremia and past virological failure and/or resistance
R. Gagliardini Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Emergence and Persistence of Integrase Mutation T97A Selected by Dolutegravir
K. Huik Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Evaluation of HIV-1 RNA and DNA mutational load in HIV-1 infected heavily treatment-experienced patients harbouring multi-drug resistant strains
D. Armenia Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Long-term Bictegravir and Dolutegravir Resistance Selections Initiated with HIV-1 Containing M184V in Reverse Transcriptase
K. White Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Molecular analysis of HCV subtype 3a dispersal patterns among inmates in Greece: HCV transmissions are not related to incarceration
E. Kostaki Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Highly sensitive digital droplet PCR assay allows to reveal cryptic HBV replication in anti-HBc positive/HBsAg negative patients with HIV infection.
L. Piermatteo Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates
A. Giannini  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry
F. Saladini Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Two-drug regimen (2DR) for initial HIV treatment? – Lessons learned from 20 years RESINA cohort
N. Lübke  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Dynamics of HIV-1 transmission clusters in North and Central Italy over the years 2012-2019
R. Scutari Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Transmitted drug resistance to integrase based first-line HIV antiretroviral treatment in the MeditRes HIV collaboration
F. García Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Exploring Molecular Characteristics and Evolutionary Dynamics of the HIV-1 Epidemic in Montenegro Through Phylogenetic Analyses
S. Dragas Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Prevalence and spatiotemporal dynamics of the HIV-1 circulating recombinant form 03_AB (CRF03_AB) in the former Soviet Union
E. Ozhmegova  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Cabotegravir + Rilpivirine Every 2 Months Is Noninferior to Monthly: ATLAS-2M Study
P. Benn Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Short- and long-term direct medical costs of late and very late HIV presentation
L. Versteegh Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Treatment outcome among people living with HIV starting first-line rapid or GRT guided ART from 2015 to 2018
A. De Vito  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients
Y. Bouba Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96
J. van Wyk Reviews in Antiviral Therapy & Infectious Diseases 7, 2020  
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Emergence of Resistance in HIV-1 Integrase following Dolutegravir Treatment in Participants Aged 4 Weeks to <18 Years: Results from the IMPAACT P1093 Study
C. Vavro Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab
H. Jullien Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations
F. Giammarino Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Detection in HIV proviral DNA of drug resistance mutations in patients with low permanent viral loads
P. Ferrer  Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020